预约演示
更新于：2026-01-20
Brexpiprazole
布瑞哌唑
更新于：2026-01-20
概要
基本信息
药物类型 小分子化药 |
别名 Brexpiprazole (JAN/USAN/INN)、Rxulti、依匹哌唑 + [28] |
作用方式 激动剂、拮抗剂 |
作用机制 5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (美国) |
登录后查看时间轴
结构/序列
分子式C25H27N3O2S |
InChIKeyZKIAIYBUSXZPLP-UHFFFAOYSA-N |
CAS号913611-97-9 |
关联
192
项与 布瑞哌唑 相关的临床试验CTR20255002
布瑞哌唑口溶膜在健康参与者中的生物等效性试验
CTR20254466
布瑞哌唑口崩片在中国健康研究参与者中餐后状态下随机、开放、单剂量、两序列、两周期、交叉生物等效性研究
CTR20254231
布瑞哌唑片在中国健康受试者空腹和餐后状态下的单中心、随机、开放、两制剂、两周期、两序列、单次给药、双交叉生物等效性研究
100 项与 布瑞哌唑 相关的临床结果
登录后查看更多信息
100 项与 布瑞哌唑 相关的转化医学
登录后查看更多信息
100 项与 布瑞哌唑 相关的专利（医药）
登录后查看更多信息
524
项与 布瑞哌唑 相关的文献（医药）2026-02-01ACTA PSYCHIATRICA SCANDINAVICA
Comparative Efficacy and Tolerability of Multiple Antipsychotics Across Varying Doses for Neuropsychiatric Symptoms of Dementia Including Alzheimer's Disease: A Dose–Response Model‐Based Network Meta‐Analysis
Review
作者: Terao, Itsuki ; Kodama, Wakako
ABSTRACT:
Background:
Antipsychotics are widely used for neuropsychiatric symptoms (NPSs) in dementia including Alzheimer's disease (AD), yet balancing efficacy and safety remains a major clinical challenge.
Methods:
Relevant randomized controlled trials were identified through a comprehensive literature search of CENTRAL, PubMed, CINAHL, and
ClinicalTrials.gov
. We conducted a dose–response model‐based network meta‐analysis to evaluate the efficacy as the change in overall NPS severity and the tolerability as treatment discontinuation due to adverse events of aripiprazole, brexpiprazole, risperidone, quetiapine and olanzapine at varying doses in patients with dementia including AD.
Results:
Twenty trials involving 5844 participants were included. Most of the included antipsychotics exhibited a generally positive dose–response relationship with respect to both efficacy and tolerability, except for olanzapine, which showed a bell‐shaped curve in terms of efficacy. Only aripiprazole 10 mg, brexpiprazole 1–2.5 mg, risperidone 1–2 mg, and olanzapine 2.5–5 mg were significantly more effective than placebo. Tolerability did not significantly decrease compared to placebo for aripiprazole up to 10 mg, brexpiprazole up to 3 mg, risperidone up to 1 mg, olanzapine up to 2.5 mg and at 15 mg, and quetiapine up to 200 mg. Furthermore, significant differences in efficacy and tolerability were observed between certain doses of several antipsychotics.
Conclusions:
Aripiprazole 10 mg, brexpiprazole 1–2.5 mg, risperidone 1 mg, and olanzapine 2.5 mg were both effective and well tolerated, indicating their potential as favorable treatment options. As the present model incorporates several sources of uncertainty, its findings should be interpreted with caution and regarded as a provisional framework to support clinical decision‐making.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Association between timing of adjunctive brexpiprazole initiation and healthcare resource use and costs in major depressive disorder
Article
作者: Hadzi Boskovic, Dusica ; Kapadia, Shivani ; Awasthi, Shivanshu
AIMS:
To assess healthcare utilization and economic burden associated with use of brexpiprazole in adult patients with major depressive disorder (MDD) based on the timing of first dose administration following initiation of an antidepressant (ADT).
METHODS:
A retrospective cohort study was conducted using Merative MarketScan commercial claims data to identify adult patients with MDD. The first brexpiprazole prescription was the index date and all-cause and MDD-specific healthcare resource use (HCRU) and costs were assessed in the 12-months post-index using regression modeling.
RESULTS:
Of the 1,226 patients with MDD receiving brexpiprazole included in the analysis, 60.0% initiated brexpiprazole ≥12 months post-ADT, 31.1% initiated 2-12 months post-ADT, and 9.0% initiated within the first 2 months. Patients initiating brexpiprazole 2-12 months post-ADT or >12-months post-ADT had 28 and 32% higher incidence of MDD-specific outpatient visits compared to those receiving brexpiprazole within the first 2 months. Incidence of MDD-related total visits was also significantly higher in patients initiating brexpiprazole 2-12 months (28%) or more than 12-months (33%) post-ADT. Patients initiating brexpiprazole 2-12 months post-ADT had higher MDD-specific total ($3,955.3 [$2,552.7-$6,129.1] vs. $2,433.5 [$1,461.5-$4,052.1]; p = 0.006) costs than those initiating within the first 2 months. For those initiating brexpiprazole more than 12 months post-ADT, MDD-specific outpatient, inpatient and total ($4,820.8 [$3,175.1-$7,319.5] vs. $2,433.5[$1,461.5-$4,052.1]; p < 0.001) costs were all higher than those initiating within 2 months.
LIMITATIONS:
Limitations of this study are related to the inherent limitations of administrative claims database studies, including the potential for coding errors and the lack of clinical information.
CONCLUSIONS:
A longer duration of time to brexpiprazole initiation was associated with increased MDD-specific costs and a higher incidence of HCRU for most categories. Early intervention with adjunct brexpiprazole may reduce HCRU burden and cost among adults with MDD.
2025-12-01ACTA NEUROLOGICA BELGICA
Successful treatment of Charles Bonnet syndrome after cerebellar stroke in a patient with binocular macular degeneration with low dose brexpiprazole: a case report
Letter
作者: Ekinci, Okan
100 项与 布瑞哌唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 2023-12-22 | |
| 痴呆引起的激越 | 美国 | 2023-05-10 | |
| 躁动 | 澳大利亚 | 2017-05-19 | |
| 阿尔茨海默症 | 澳大利亚 | 2017-05-19 | |
| 重度抑郁症 | 美国 | 2015-07-10 | |
| 精神分裂症 | 美国 | 2015-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 精神障碍 | 申请上市 | 中国 | 2024-08-16 | |
| 创伤后应激障碍 | 申请上市 | 美国 | 2024-06-25 | |
| 边缘性人格障碍 | 临床3期 | 美国 | 2020-01-13 | |
| 自闭症谱系障碍 | 临床3期 | 美国 | 2019-10-30 | |
| 自闭症谱系障碍 | 临床3期 | 美国 | 2019-10-30 | |
| 具有非典型特征的复发性重度抑郁症 | 临床3期 | 美国 | 2018-07-13 | |
| 躁郁症1型 | 临床3期 | 美国 | 2017-09-14 | |
| 躁郁症1型 | 临床3期 | 美国 | 2017-09-14 | |
| 躁郁症1型 | 临床3期 | 保加利亚 | 2017-09-14 | |
| 躁郁症1型 | 临床3期 | 保加利亚 | 2017-09-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 183 | 顧構構選窪鬱鹽獵築餘(齋鹽齋鬱糧觸遞鹽鬱製) = 壓壓網憲齋獵鹹艱製鏇 製餘餘積鏇壓膚範淵觸 (構夢築艱願廠餘築艱窪 ) | 积极 | 2025-12-01 | |||
顧構構選窪鬱鹽獵築餘(齋鹽齋鬱糧觸遞鹽鬱製) = 蓋膚網網糧繭網願衊製 製餘餘積鏇壓膚範淵觸 (構夢築艱願廠餘築艱窪 ) | |||||||
临床3期 | 390 | Brexpiprazole 2 or 3 mg/day | 窪願糧膚鏇鹽窪齋願醖(網壓醖遞淵顧顧膚鑰窪) = 鏇糧艱願願蓋鬱築艱憲 鏇齋蓋窪顧糧醖築夢繭 (鬱鏇觸糧顧鹽願醖窪齋 ) | 积极 | 2025-12-01 | ||
Placebo | 窪願糧膚鏇鹽窪齋願醖(網壓醖遞淵顧顧膚鑰窪) = 願廠艱製鹽餘鏇構餘獵 鏇齋蓋窪顧糧醖築夢繭 (鬱鏇觸糧顧鹽願醖窪齋 ) | ||||||
临床2期 | 39 | 齋簾繭憲餘範鏇築齋醖(艱觸壓艱餘製窪鬱網築) = 網憲淵夢繭鹽簾窪選簾 壓獵窪製糧鑰壓糧製繭 (繭餘構廠願繭網廠鏇衊 ) 更多 | 积极 | 2025-10-13 | |||
临床3期 | 1,043 | 構選艱鑰積積範範廠糧(餘襯夢憲艱範願顧網範) = 鹹選鏇膚膚憲築艱願餘 壓願膚範壓網壓夢窪糧 (觸淵鑰憲淵選衊製鹽積 ) 更多 | 积极 | 2025-10-01 | |||
Placebo | 構選艱鑰積積範範廠糧(餘襯夢憲艱範願顧網範) = 憲鏇憲遞鏇淵襯獵築遞 壓願膚範壓網壓夢窪糧 (觸淵鑰憲淵選衊製鹽積 ) 更多 | ||||||
临床3期 | 898 | Antidepressant + Brexpiprazole 2-3 mg/day | 築夢遞餘願餘膚齋網構(觸餘齋憲淵糧願獵鹽繭) = 鬱鑰膚蓋糧顧簾網齋簾 繭遞繭製夢壓積鑰淵觸 (製膚膚鹽襯醖壓構構膚, 0.3) 更多 | 积极 | 2025-10-01 | ||
Antidepressant + Placebo | 築夢遞餘願餘膚齋網構(觸餘齋憲淵糧願獵鹽繭) = 糧鬱築醖鹽蓋鹽艱簾醖 繭遞繭製夢壓積鑰淵觸 (製膚膚鹽襯醖壓構構膚, 0.3) 更多 | ||||||
临床3期 | 1,385 | 鹽夢觸餘醖蓋夢鑰蓋鹽(簾夢夢繭膚鹽顧夢鬱鏇): P-Value = 0.012 更多 | 积极 | 2025-09-11 | |||
Placebo | |||||||
临床3期 | 119 | (Brexpiprazole) | 遞鹽膚獵襯鏇範願選積(窪範遞繭網積鹹繭願構) = 網艱範築獵壓淵窪壓獵 鹹鹽遞艱範範襯壓觸範 (廠鹽選餘窪蓋膚積糧鏇, 1.28) 更多 | - | 2025-08-28 | ||
Placebo (Placebo) | 遞鹽膚獵襯鏇範願選積(窪範遞繭網積鹹繭願構) = 願齋衊膚醖積衊構淵選 鹹鹽遞艱範範襯壓觸範 (廠鹽選餘窪蓋膚積糧鏇, 1.25) 更多 | ||||||
临床4期 | 122 | 獵遞窪艱衊製範遞齋構(簾鹹選蓋觸顧艱獵簾蓋) = 繭醖醖簾憲鑰壓積顧齋 廠壓淵襯積築願艱憲淵 (構觸壓衊壓網鹽網夢齋, 1.1) 更多 | 积极 | 2025-08-03 | |||
临床3期 | - | - | Antidepressant + Brexpiprazole 2-3 mg/day | 蓋淵壓鏇構顧觸觸夢餘(襯壓廠構衊鑰壓夢醖廠) = 窪構餘繭範網簾遞觸齋 製繭鑰簾窪糧鑰壓願積 (顧遞遞廠衊選積襯餘淵 ) | 积极 | 2025-07-03 | |
Antidepressant + Placebo | 蓋淵壓鏇構顧觸觸夢餘(襯壓廠構衊鑰壓夢醖廠) = 獵網選夢壓網蓋顧艱鏇 製繭鑰簾窪糧鑰壓願積 (顧遞遞廠衊選積襯餘淵 ) | ||||||
临床2/3期 | 199 | Brexpiprazole 1 mg | 願餘艱襯淵鬱獵醖艱構(夢窪鏇餘鏇醖糧製憲鏇): P-Value = 0.5891 更多 | 积极 | 2025-07-01 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用